This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/drugbank/drug/DB05508/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05508/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB05508/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05508
rdf:type
n5:Drug
n5:description
PTI-901 (low-dose naltrexone HCI) is Pain Therapeutics' novel drug candidate to treat men or women with IBS. It is believed that an imbalance of opioid activity in the gut contributes to the symptoms that comprise IBS. Such an imbalance may be triggered by emotional stress, metabolic disorders or intrinsic release of opioids from neurons in the gut. PTI-901 is the first in a new class of drugs called opioid antagonists designed to restore the balance of opioid activity in the gut. By restoring this imbalance, PTI-901 relieves abdominal pain and other symptoms frequently observed in patients with IBS.
n5:generalReferences
# Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z: Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci. 2006 Dec;51(12):2128-33. Epub 2006 Nov 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17080248
n5:group
investigational
n5:indication
Investigated for use/treatment in irritable bowel syndrome (IBS).
owl:sameAs
n10:DB05508
dcterms:title
PTI-901
adms:identifier
n4:5485201 n7:4588651 n8:DB05508
n5:mechanismOfAction
PTI-901 is the first in a new class of drugs called opioid antagonists designed to restore the balance of opioid activity in the gut
n5:IUPAC-Name
n6:271B4575-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B457B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B457A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4577-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4578-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4579-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4574-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B4581-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4582-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B457C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B457D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B457F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B457E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4580-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4587-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4589-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B458A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4586-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4585-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4588-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4576-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4583-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4584-363D-11E5-9242-09173F13E4C5